Even though T cells significantly expanded with combination XmAb808 and anti–PD-1 treatment, symptoms of GVHD such as weight loss did not differ between treatment groups, suggesting that the expanded T cells primarily targeted the tumor rather than the host. The gene discussed is PDCD1; the disease is graft versus host disease.